| Reviewer | Employment | Consultant | Speakers Bureau | Ownership/Partnership/Principal | Personal Research | Institutional, Organizational, or Other Financial Benefit | Expert Witness |
|---|---|---|---|---|---|---|---|
| David P. Faxon, Peer Review Committee Chair | Harvard University; Brigham and Women’s Hospital | None | None | • REVA Medical | • Boston Scientific (DSMB) • CSL Behring (DSMB) • Medtronic (DSMB)* |
None | None |
| Gilbert R. Upchurch Jr, Peer Review Committee Vice Chair | University of Florida College of Medicine | None | None | • Antyllus* | • NIH, PI* | • Bolton† • Cook† • Gore† • Medtronic† |
None |
| Aaron W. Aday | Vanderbilt University Medical Center | • OptumCare‡ • TransThera Sciences |
None | None | • Janssen Pharmaceuticals† • University of Manitoba† |
None | |
| Ali Azizzadeh | Cedars Sinai | None | None | None | None | • Gore† | None |
| Michael Boisen (representing SCA) | University of Pittsburgh | None | None | None | None | None | None |
| Mohammad H. Eslami (representing SVS) | University of Pittsburgh | None | None | None | None | None | None |
| Beau Hawkins (representing SVM) | The University of Oklahoma College of Medicine | • Baim Institute for Clinical Research | None | None | None | • Behring† • Boston Scientific† • Hemostemix† • NIH† |
None |
| Christopher M. Kramer | University of Virginia | • Bristol Myers Squibb‡ • Cytokinetics • Eli Lilly • Xencor |
None | None | • NHLBI‡ • NIBIB‡ |
• Cytokinetics† • MyoKardia† |
None |
| Jessica G. Y. Luc | University of British Columbia | None | None | None | None | None | None |
| Thomas E. MacGillivary (representing STS) | Houston Methodist | None | None | None | None | • Xylocor† | None |
| S. Christopher Malaisrie (representing AATS) | Northwestern University | • Artivion • Medtronic |
• Edwards Lifesciences‡ • Terumo |
None | • Artivion‡ • Atricure • Edwards Lifesciences‡ • Terumo‡ |
• Artivion† • Edwards Lifesciences† • Medtronic† |
None |
| Kathryn Osteen | Baylor University Louise Herrington School of Nursing | None | None | None | None | • AHA* • Congenital Heart Public Health Consortium* • Sigma Theta Tau-Eta Gamma Chapter* • The Children’s Heart Foundation* |
None |
| Himanshu J. Patel | University of Michigan Health | • Edwards Lifesciences • Gore • Medtronic‡ • Terumo |
None | None | None | • Edwards Lifesciences† • Gore† • Medtronic† • Nexus† |
None |
| Parag J. Patel (representing SIR) | Medical College of Wisconsin | None | None | None | None | • AHA* • SIR* |
None |
| Wanda M. Popescu (representing SCA) | Yale School of Medicine | None | None | None | None | • Ambu, Advisory Board Member | None |
| Evelio Rodriguez | Ascension Tennessee Saint Thomas Hospital | • Abbott‡ • Edwards Lifesciences‡ |
• Abbott‡ • Edwards Lifesciences‡ • Philips‡ |
None | • Abbott • Atricure • Boston Scientific • Claret • Direct Flow • Edwards Lifesciences‡ • Medtronic |
• Abbott† • Atricure† • Boston Scientific† • Edwards Lifesciences† • Medtronic† |
None |
| Rebecca Sorber | Johns Hopkins University School of Medicine | None | None | None | None | None | None |
| Philip S. Tsao | VA Palo Alto Health Care System; Stanford University School of Medicine | None | None | None | None | None | None |
| Annabelle Santos Volgman | Rush College of Medicine | • Bristol Myers Squibb, DCICDP • Janssen Pharmaceuticals • Merck • Pfizer • Sanofi‡ |
None | None | • NIH‡ | • Apple* • Novartis† |
None |
This table represents all reviewers’ relationships with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/ relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.
No financial benefit.
This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for Writing Committees.
Significant relationship.
AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; DCICDP, Diverse Clinical Investigator Career Development Program; DSMB, data and safety monitoring board; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; NIBIB, National Institute of Biomedical Imaging and Bioengineering; PRC, Peer Review Committee; PI, principal investigator; SCA, Society of Cardiovascular Anesthesiologists; SIR, Society of Interventional Radiology; STS, Society of Thoracic Surgeons; SVM, Society for Vascular Medicine; SVS, Society for Vascular Surgery; and VA, Veterans Affairs.